Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine

References

• Brentjens MH , Yeung-Yue KA , Lee PC , Tyring SK. Human papillomavirus: a review. Dermatol Clin 2002; 20(2):315-31; PMID:12120445; https://doi.org/10.1016/S0733-8635(01)00028-6
   PubMed Web of Science ®Google Scholar
• Wiley D , Masongsong E . Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006; 61(6 Suppl 1):S3-14; PMID:16729902; https://doi.org/10.1097/01.ogx.0000221010.82943.8c
   PubMed Web of Science ®Google Scholar
• zur Hausen H , Gissmann L , Steiner W , Dippold W , Dreger I . Human papilloma viruses and cancer. Bibl Haematol 1975; (43):569-71; PMID:183728; https://doi.org/10.1159/000399220
   PubMedGoogle Scholar
• zur Hausen H . Oncogenic Herpes viruses. Biochim Biophys Acta 1975; 417(1):25-53; PMID:164249; https://doi.org/10.1016/0304-419X(75)90007-4
   PubMed Web of Science ®Google Scholar
• World Health Organization . Human papillomavirus (HPV) and cervical cancer. Updated June 2016; http://www.who.int/mediacentre/factsheets/fs380/en/ (Accessed on 20 April 2017 )
   Google Scholar
• Ferlay J , Soerjomataram I , Dikshit R , Eser S , Mathers C , Rebelo M , Parkin DM , Forman D , Bray F . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5):E359-386; PMID:25220842; https://doi.org/10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Mariani L , Preti M , Cristoforoni P , Stigliano CM , Perino A . Overview of the benefits and potential issues of the nonavalent HPV vaccine. Int J Gynaecol Obstet 2017; 136(3):258-65; PMID:28087890; https://doi.org/10.1002/ijgo.12075
   PubMed Web of Science ®Google Scholar
• Harper DM . Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009; 8(12):1663-79; PMID:19943762; https://doi.org/10.1586/erv.09.123
   PubMed Web of Science ®Google Scholar
• Guan P , Howell-Jones R , Li N , Bruni L , de Sanjosé S , Franceschi S , Clifford GM . Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131(10):2349-59; PMID:22323075; https://doi.org/10.1002/ijc.27485
   PubMed Web of Science ®Google Scholar
• Wheeler CM , Hunt WC , Cuzick J , Langsfeld E , Pearse A , Montoya GD , Robertson M , Shearman CA , Castle PE . A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer 2013; 132(1):198-207; PMID:22532127; https://doi.org/10.1002/ijc.27608
   PubMed Web of Science ®Google Scholar
• McCormack PL . Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs 2014; 74(11):1253-83; PMID:25022951; https://doi.org/10.1007/s40265-014-0255-z
   PubMed Web of Science ®Google Scholar
• Garland SM , Kjaer SK , Muñoz N , Block SL , Brown DR , DiNubile MJ , Lindsay BR , Kuter BJ , Perez G , Dominiak-Felden G , et al. Impact and effectiveness of the Quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience. Clin Infect Dis 2016; 63(4):519-27; PMID:27230391; https://doi.org/10.1093/cid/ciw354
   PubMed Web of Science ®Google Scholar
• Muñoz N , Bosch FX , Castellsagué X , Díaz M , de Sanjose S , Hammouda D , Shah KV , Meijer CJ . Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111(2):278-85; PMID:15197783; https://doi.org/10.1002/ijc.20244
   PubMed Web of Science ®Google Scholar
• de Sanjose S , Quint WG , Alemany L , Geraets DT , Klaustermeier JE , Lloveras B , Tous S , Felix A , Bravo LE , Shin HR , et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11(11):1048-56; PMID:20952254; https://doi.org/10.1016/S1470-2045(10)70230-8
   PubMed Web of Science ®Google Scholar
• Malagón T , Drolet M , Boily MC , Franco EL , Jit M , Brisson J , Brisson M . Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12(10):781-9; PMID:22920953; https://doi.org/10.1016/S1473-3099(12)70187-1
   PubMed Web of Science ®Google Scholar
• Dochez C , Bogers JJ , Verhelst R , Rees H . HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine 2014; 32(14):1595-601; PMID:24606637; https://doi.org/10.1016/j.vaccine.2013.10.081
   PubMed Web of Science ®Google Scholar
• Einstein MH , Baron M , Levin MJ , Chatterjee A , Fox B , Scholar S , Rosen J , Chakhtoura N , Lebacq M , van der Most R , et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7(12):1359-73; PMID:22048172; https://doi.org/10.4161/hv.7.12.18282
   PubMed Web of Science ®Google Scholar
• Einstein MH , Baron M , Levin MJ , Chatterjee A , Fox B , Scholar S , Rosen J , Chakhtoura N , Meric D , Dessy FJ , et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011; 7(12):1343-58; PMID:22048173; https://doi.org/10.4161/hv.7.12.18281
   PubMed Web of Science ®Google Scholar
• Broad spectrum HPV vaccine dose ranging study (V502-001) . ClinicalTrials.gov Identifier: NCT00260039; Last updated: 2015 June 5 ; [Accessed on 20 April 2017 ]. https://clinicaltrials.gov/ct2/show/NCT00260039?term=v502-001&rank=1
   Google Scholar
• Broad spectrum HPV (human papillomavirus) vaccine study in 16-to 26-year-old women (V503-001) . ClinicalTrials.gov Identifier: NCT00543543; Last updated: 2017 March 24 ; [Accessed on 20 April 2017 ]. https://clinicaltrials.gov/ct2/show/NCT00543543?term=v503-001&rank=2
   Google Scholar
• A study to evaluate tolerability and immunogenicity of V504 administered concomitantly with GARDASIL (V504-001). ClinicalTrials.gov Identifier: NCT00551187; Last updated: 2015 June 5 ; [Accessed on 20 April 2017 ]. https://clinicaltrials.gov/ct2/show/NCT00551187?term=v504-001&rank=1
   Google Scholar
• Luxembourg A , Brown D , Bouchard C , Giuliano AR , Iversen OE , Joura EA , Penny ME , Restrepo JA , Romaguera J , Maansson R , et al. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine. Hum Vaccin Immunother 2015; 11(6):1313-22; PMID:25912208; https://doi.org/10.1080/21645515.2015.1012010
   PubMed Web of Science ®Google Scholar
• Audisio RA , Icardi G , Isidori AM , Liverani CA , Lombardi A , Mariani L , Mennini FS , Mitchell DA , Peracino A , Pecorelli S , et al. Public health value of universal HPV vaccination. Crit Rev Oncol Hematol 2016; 97:157-67; PMID:26346895; https://doi.org/10.1016/j.critrevonc.2015.07.015
   PubMed Web of Science ®Google Scholar
• Gupta G , Glueck R , Patel PR . HPV vaccines: Global perspectives. Hum Vaccin Immunother 2017; 13(6):1-4; PMID:28362244; https://doi.org/10.1080/21645515.2017.1289301
   PubMed Web of Science ®Google Scholar
• Schuchat A . HPV “coverage.” N Engl J Med 2015; 372(8):775-6; PMID:25693018; https://doi.org/10.1056/NEJMe1415742
   PubMed Web of Science ®Google Scholar
• Serrano B , Alemany L , Tous S , Bruni L , Clifford GM , Weiss T , Bosch FX , de Sanjosé S . Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7(1):38; PMID:23273245; https://doi.org/10.1186/1750-9378-7-38
   PubMed Web of Science ®Google Scholar
• Joura EA , Ault KA , Bosch FX , Brown D , Cuzick J , Ferris D , Garland SM , Giuliano AR , Hernandez-Avila M , Huh W , et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev 2014; 23(10):1997-2008; PMID:25274978; https://doi.org/10.1158/1055-9965.EPI-14-0410
   PubMed Web of Science ®Google Scholar
• Alemany L , Saunier M , Tinoco L , Quirós B , Alvarado-Cabrero I , Alejo M , Joura EA , Maldonado P , Klaustermeier J , Salmerón J , et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 2014; 50(16):2846-54; PMID:25155250; https://doi.org/10.1016/j.ejca.2014.07.018
   PubMed Web of Science ®Google Scholar
• de Sanjosé S , Alemany L , Ordi J , Tous S , Alejo M , Bigby SM , Joura EA , Maldonado P , Laco J , Bravo IG , et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013; 49(16):3450-61; PMID:23886586; https://doi.org/10.1016/j.ejca.2013.06.033
   PubMed Web of Science ®Google Scholar
• Alemany L , Saunier M , Alvarado-Cabrero I , Quirós B , Salmeron J , Shin HR , Pirog EC , Guimerà N , Hernandez-Suarez G , Felix A , et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015; 136(1):98-107; PMID:24817381; https://doi.org/10.1002/ijc.28963
   PubMed Web of Science ®Google Scholar
• Garland SM , Steben M , Sings HL , James M , Lu S , Railkar R , Barr E , Haupt RM , Joura EA . Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199(6):805-14; PMID:19199546; https://doi.org/10.1086/597071
   PubMed Web of Science ®Google Scholar
• Bonanni P , Bechini A , Donato R , Capei R , Sacco C , Levi M , Boccalini S . Human papilloma virus vaccination: impact and recommendations across the world. Ther Adv Vaccines 2015; 3(1):3-12; PMID:25553242; https://doi.org/10.1177/2051013614557476
   PubMedGoogle Scholar
• Shank-Retzlaff ML , Wang F , Morley T , Anderson C , Hamm M , Brown M , Rowland K , Pancari G , Zorman J , Lowe R , et al. Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples. Hum Vaccin 2005; 1(5):191-7; PMID:17012876; https://doi.org/10.4161/hv.1.5.2126
   PubMed Web of Science ®Google Scholar
• Shank-Retzlaff ML , Zhao Q , Anderson C , Hamm M , High K , Nguyen M , Wang F , Wang N , Wang B , Wang Y , et al. Evaluation of the thermal stability of Gardasil. Hum Vaccin 2006; 2(4):147-54; PMID:17012891; https://doi.org/10.4161/hv.2.4.2989
   PubMed Web of Science ®Google Scholar
• Nunnally BK , Turula VE , Sitrin RD . Vaccine Analysis: Strategies, Principles, and Control. Springer-Verlag Berlin Heidelberg; 2015; https://doi.org/10.1007/978-3-662-45024-6
   Google Scholar
• Smith JF , Kowalski R , Esser MT , Brown MJ , Bryan JT . Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin 2008; 4(2):134-42; PMID:18388490; https://doi.org/10.4161/hv.4.2.5261
   PubMed Web of Science ®Google Scholar
• Christensen ND , Reed CA , Cladel NM , Hall K , Leiserowitz GS . Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type specific epitopes on HPV-6. Virology 1996; 224:477-86; PMID:8874508; https://doi.org/10.1006/viro.1996.0554
   PubMed Web of Science ®Google Scholar
• Christensen ND , Kreider JW , Cladel NM , Patrick SD , Welsh PA . Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 1990; 64:5678-81; PMID:2170694; http://jvi.asm.org/content/64/11/5678.long
   PubMed Web of Science ®Google Scholar
• Christensen ND , Dillner J , Eklund C , Carter JJ , Wipf GC , Reed CA , Cladel NM , Galloway DA . Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996; 223:174-84; PMID:8806551; https://doi.org/10.1006/viro.1996.0466
   PubMed Web of Science ®Google Scholar
• Brown MJ , Seitx H , Towne V , Muller M , Finnefrock AC . Development of neutralizing monoclonal antibodies for oncogenic HPV types 31, 33, 45, 52, and 58. Clin Vaccine Immunol 2014; 21:587-93; PMID:24574536; https://doi.org/10.1128/CVI.00773-13
   PubMed Web of Science ®Google Scholar
• Roberts C , Green T , Hess E , Matys K , Brown MJ , Haupt RM , Luxembourg A , Vuocolo S , Saah A , Antonello J . Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Hum Vaccin Immunother 2014; 10(8):2168-74; PMID:25424920; https://doi.org/10.4161/hv.29205
   PubMed Web of Science ®Google Scholar
• Opalka D , Lachman CE , MacMullen SA , Jansen KU , Smith JF , Chirmule N , Esser MT . Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10(1):108-15; PMID:12522048; http://cvi.asm.org/content/10/1/108.long
   PubMedGoogle Scholar
• Dias D , Van Doren J , Schlottmann S , Kelly S , Puchalski D , Ruiz W , Boerckel P , Kessler J , Antonello JM , Green T , et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12(8):959-69; PMID:16085914; https://doi.org/10.1128/CDLI.12.8.959-969.2005
   PubMedGoogle Scholar
• Zhao Q , Potter CS , Carragher B , Lander G , Sworen J , Towne V , Abraham D , Duncan P , Washabaugh MW , Sitrin RD . Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy. Hum Vaccin Immunother 2014; 10(3):734-9; PMID:24299977; https://doi.org/10.4161/hv.27316
   PubMed Web of Science ®Google Scholar
• Gardasil9(Human Papillomavirus 9-valent Vaccine, Recombinant) . Food and Drug Administration: Vaccines, Blood & Biologics; Vaccines; Approved products; Last Updated. 2016; [Accessed on 20 April 2017 ]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf
   Google Scholar
• A study of V503 (A multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] Vaccine) in pre-adolescents and adolescents (V503-002). ClinicalTrials.gov Identifier: NCT00943722; Last updated: 2017 March 20 ; [Accessed on 20 April 2017 ]. https://clinicaltrials.gov/ct2/show/NCT00943722?term=V503-002&rank=1
   Google Scholar
• Multivalent HPV (human papillomavirus) vaccine study in 16- to 26-year old men and women (V503-003). ClinicalTrials.gov Identifier: NCT01651949; Last updated: 2017 March 23 ; [Accessed on 20 April 2017 ]. https://clinicaltrials.gov/ct2/show/NCT01651949?term=v503-003&rank=1
   Google Scholar
• A study of V503 given concomitantly with Menactra™ and Adacel™ in 11 to 15 year olds (V503-005). ClinicalTrials.gov Identifier: NCT00988884; Last updated: 2017 March 20 ; [Accessed on 20 April 2017 ]. https://clinicaltrials.gov/ct2/show/NCT00988884?term=v503-005&rank=1
   Google Scholar
• A study of V503, a 9-valent human papillomavirus (9vHPV) vaccine in females 12-26 years of age who have previously received GARDASIL™ (V503-006). ClinicalTrials.gov Identifier: NCT01047345; Last updated: 2017 March 23 ; [Accessed on 20 April 2017 ]. https://clinicaltrials.gov/ct2/show/NCT01047345?term=v503-006&rank=1
   Google Scholar
• A study of V503 vaccine given concomitantly with REPEVAX™ in 11 to 15 year olds (V503-007). ClinicalTrials.gov Identifier: NCT01073293; Last updated: 2017 March 20 ; [Accessed on 20 April 2017 ]. https://clinicaltrials.gov/ct2/show/NCT01073293?term=v503-007&rank=1
   Google Scholar
• Immunogenicity and tolerability of V503 versus GARDASIL (V503-009). ClinicalTrials.gov Identifier: NCT01304498; Last updated: 2017 March 7 ; [Accessed on 20 April 2017 ]. https://clinicaltrials.gov/ct2/show/NCT01304498?term=v503-009&rank=1
   Google Scholar
• Moreira ED, Jr , Block SL , Ferris D , Giuliano AR , Iversen OE , Joura EA , Kosalaraksa P , Schilling A , Van Damme P , Bornstein J , et al. Safety profile of the 9-Valent HPV vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics 2016; 138(2):e20154387; PMID:27422279; https://doi.org/10.1542/peds.2015-4387
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P , Velicer C , Luxembourg A . 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Rev Vaccines 2015; 14(11):1405-19; PMID:26366475; https://doi.org/10.1586/14760584.2015.1089174
   PubMed Web of Science ®Google Scholar
• Lopalco PL . Spotlight on the 9-valent HPV vaccine. Drug Des Devel Ther 2016; 11:35-44; PMID:28053505; https://doi.org/10.2147/DDDT.S91018
   PubMed Web of Science ®Google Scholar
• Luxembourg A , Bautista O , Moeller E , Ritter M , Chen J . Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine. Contemp Clin Trials 2015; 42:18-25; PMID:25749310; https://doi.org/10.1016/j.cct.2015.02.009
   PubMed Web of Science ®Google Scholar
• Vesikari T , Brodszki N , Van Damme P , Diez-Domingo J , Icardi G , Petersen LK , Tran C , Thomas S , Luxembourg A , Baudin M . A Randomized, Double-Blind, Phase III study of the immunogenicity and safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Pediatr Infect Dis J 2015; 34(9):992-8; PMID:26090572; https://doi.org/10.1097/INF.0000000000000773
   PubMed Web of Science ®Google Scholar
• Drolet M , Bénard É , Boily MC , Ali H , Baandrup L , Bauer H , Beddows S , Brisson J , Brotherton JM , Cummings T , et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15(5):565-80; https://doi.org/10.1016/S1473-3099(14)71073-4
   PubMed Web of Science ®Google Scholar
• Petersen LK , Restrepo J , Moreira ED, Jr , Iversen OE , Pitisuttithum P , Van Damme P , Joura EA , Olsson SE , Ferris D , Block S , et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials. Papillomavirus Res 2017; 3:105-15; https://doi.org/10.1016/j.pvr.2017.03.002
   PubMed Web of Science ®Google Scholar
• Van Damme P , Olsson SE , Block S , Castellsague X , Gray GE , Herrera T , Huang LM , Kim DS , Pitisuttithum P , Chen J , et al. Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics 2015; 136(1):e28-39; PMID:26101366. https://doi.org/10.1542/peds.2014-3745
   PubMed Web of Science ®Google Scholar
• Castellsagué X , Giuliano AR , Goldstone S , Guevara A , Mogensen O , Palefsky JM , Group T , Shields C , Liu K , Maansson R , et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine 2015; 33(48):6892-901; PMID:26144901; https://doi.org/10.1016/j.vaccine.2015.06.088
   PubMed Web of Science ®Google Scholar
• Van Damme P , Meijer CJ , Kieninger D , Schuyleman A , Thomas S , Luxembourg A , Baudin M . A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine 2016; 34(35):4205-12; PMID:27354258; https://doi.org/10.1016/j.vaccine.2016.06.056
   PubMed Web of Science ®Google Scholar
• Chatterjee A . The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines 2014; 13(11):1279-90; PMID:25256262; https://doi.org/10.1586/14760584.2014.963561
   PubMed Web of Science ®Google Scholar
• A phase III study of a 2-dose regimen of a multivalent human papillomavirus (HPV) vaccine (V503), administered to 9 to 14 year-olds and compared to young women, 16 to 26 years old (V503-010). ClinicalTrials.gov Identifier: NCT01984697; Last updated: 2017 March 9 ; [Accessed on 20 April 2017 ]. https://clinicaltrials.gov/ct2/show/NCT01984697?term=v503-010&rank=1
   Google Scholar
• Iversen OE , Miranda MJ , Ulied A , Soerdal T , Lazarus E , Chokephaibulkit K , Block SL , Skrivanek A , Nur Azurah AG , Fong SM , et al. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA 2016; 316(22):2411-21; PMID:27893068; https://doi.org/10.1001/jama.2016.17615
   PubMed Web of Science ®Google Scholar
• Tejada RA , Vargas KG , Benites-Zapata V , Mezones-Holguín E , Bolaños-Díaz R , Hernandez AV . Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis. Salud Publica Mex 2017; 59(1):84-94; PMID:28423114; https://doi.org/10.21149/7824
   PubMed Web of Science ®Google Scholar
• Hermann JS , Weckx LY , Monteiro Nürmberger J , Santos Junior GF , Campos Pignatari AC , Nagata Pignatari SS . Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2016; 83:94-8; PMID:26968061; https://doi.org/10.1016/j.ijporl.2016.01.032
   PubMed Web of Science ®Google Scholar
• Tay SK , Hsu TY , Shcheprov A , Walia A , Kulkarni AS . The clinical and economic benefits of school-based quadrivalent HPV vaccination in Singapore. Int J Gynaecol Obstet 2017; 137(2):129-37; PMID:28190260; https://doi.org/10.1002/ijgo.12126
   PubMed Web of Science ®Google Scholar
• Garland SM , Cheung TH , McNeill S , Petersen LK , Romaguera J , Vazquez-Narvaez J , Bautista O , Shields C , Vuocolo S , Luxembourg A . Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine 2015; 33(48):6855-64; PMID:26411885; https://doi.org/10.1016/j.vaccine.2015.08.059
   PubMed Web of Science ®Google Scholar
• Reisinger KS , Block SL , Collins-Ogle M , Marchant C , Catlett M , Radley D , Sings HL , Haupt RM , Garner EI , Protocol 025 Investigators . Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel. Pediatrics 2010; 125(6):1142-51; https://doi.org/10.1542/peds.2009-2336
   PubMed Web of Science ®Google Scholar
• Harper DM , Vierthaler SL , Santee JA . Review of Gardasil. J Vaccines Vaccin 2010; 1(107) pii: 1000107; PMID:23805398; https://doi.org/10.4172/2157-7560.1000107
   PubMedGoogle Scholar
• Wheeler CM , Harvey BM , Pichichero ME , Simon MW , Combs SP , Blatter MM , Marshall GS , Catteau G , Dobbelaere K , Descamps D , et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J 2011; 30(12):e225-234; PMID:21817954; https://doi.org/10.1097/INF.0b013e31822d28df
   PubMed Web of Science ®Google Scholar
• Noronha AS , Markowitz LE , Dunne EF . Systematic review of human papillomavirus vaccine coadministration. Vaccine 2014; 32(23):2670-4; PMID:24412351; https://doi.org/10.1016/j.vaccine.2013.12.037
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P , Mehlsen J , Vesikari T , Forstén A , Helm K , Van Damme P , Joura EA , Ciprero K , Maansson R , Luxembourg A , et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J 2015; 34(6):627-34; PMID:25831420; https://doi.org/10.1097/INF.0000000000000694
   PubMed Web of Science ®Google Scholar
• Schilling A , Parra MM , Gutierrez M , Restrepo J , Ucros S , Herrera T , Engel E , Huicho L , Shew M , Maansson R , et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics 2015; 136(3):e563-572; PMID:26240207; https://doi.org/10.1542/peds.2014-4199
   PubMed Web of Science ®Google Scholar
• Saslow D , Andrews KS , Manassaram-Baptiste D , Loomer L , Lam KE , Fisher-Borne M , Smith RA , Fontham ET , American Cancer Society Guideline Development Group . Human papillomavirus vaccination guideline update: American cancer society guideline endorsement. CA Cancer J Clin 2016; 66(5):375-85; PMID:27434803; https://doi.org/10.3322/caac.21355
   PubMed Web of Science ®Google Scholar
• Pils S , Joura EA . From the monovalent to the nine-valent HPV vaccine. Clin Microbiol Infect 2015; 21(9):827-33; https://doi.org/10.1016/j.cmi.2015.05.001
   PubMed Web of Science ®Google Scholar
• Petrosky E , Bocchini JA, Jr , Hariri S , Chesson H , Curtis CR , Saraiya M , Unger ER , Markowitz LE . Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64(11):300-4; PMID:25811679; https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.html
   PubMed Web of Science ®Google Scholar
• National Center for Immunization Research & Surveillance . Human papillomavirus (HPV) vaccines for Australians: information for immunization providers. Available from: http://ncirs.edu.au/assets/provider_resources/fact-sheets/human-papillomavirus-hpv-fact-sheet.pdf [Accessed on 20 April 2017 ]
   Google Scholar
• European Medicines Agency . Committee for Medicinal Products for Human Use (CHMP). Gardasil 9® International non-proprietary name: human papillomavirus 9-valent vaccine. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003852/WC500189113.pdf [Accessed on 20 April 2017 ]
   Google Scholar
• Meites E , Kempe A , Markowitz LE . Use of a 2-Dose Schedule for Human Papillomavirus vaccination-updated recommendations of the advisory committee on immunization practices. Am J Transplant 2017; 17(3):834-7; PMID:28240827; https://doi.org/10.1111/ajt.14206
   PubMed Web of Science ®Google Scholar
• Eltoum IA , Roberson J . Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS). Cancer 2007; 111(1):34-40; PMID:17262799; https://doi.org/10.1002/cncr.22487
   PubMed Web of Science ®Google Scholar
• Kulasingam S , Connelly L , Conway E , Hocking JS , Myers E , Regan DG , Roder D , Ross J , Wain G . A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian national cervical cancer screening program. Sex Health 2007; 4(3):165-75; PMID:17931529; https://doi.org/10.1071/SH07043
   PubMed Web of Science ®Google Scholar
• Techakehakij W , Feldman RD . Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine 2008; 26(49):6258-65; PMID:18835313; https://doi.org/10.1016/j.vaccine.2008.09.036
   PubMed Web of Science ®Google Scholar
• Brotherton JM , Fridman M , May CL , Chappell G , Saville AM , Gertig DM . Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377(9783):2085-92; PMID:21684381; https://doi.org/10.1016/S0140-6736(11)60551-5
   PubMed Web of Science ®Google Scholar
• Chesson HW , Markowitz LE , Hariri S , Ekwueme DU , Saraiya M . The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model. Hum Vaccin Immunother 2016; 12(6):1363-72; PMID:26890978; https://doi.org/10.1080/21645515.2016.1140288
   PubMed Web of Science ®Google Scholar
• Durham DP , Ndeffo-Mbah ML , Skrip LA , Jones FK , Bauch CT , Galvani AP . National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proc Natl Acad Sci USA 2016; 113(18):5107-12; PMID:27091978; https://doi.org/10.1073/pnas.1515528113
   PubMed Web of Science ®Google Scholar
• Brisson M , Laprise JF , Chesson HW , Drolet M , Malagón T , Boily MC , Markowitz LE . Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. J Natl Cancer Inst 2015; 108(1):djv282; PMID:26438574; https://doi.org/10.1093/jnci/djv282
   PubMedGoogle Scholar
• Largeron N , Petry KU , Jacob J , Bianic F , Anger D , Uhart M . An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res 2017; 17(1):85-98; PMID:27366939; https://doi.org/10.1080/14737167.2016.1208087
   PubMed Web of Science ®Google Scholar
• Boiron L , Joura E , Largeron N , Prager B , Uhart M . Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect Dis 2016; 16:153; PMID:27084683; https://doi.org/10.1186/s12879-016-1483-5
   PubMed Web of Science ®Google Scholar
• Drolet M , Laprise JF , Boily MC , Franco EL , Brisson M . Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 2014; 134(9):2264-8; PMID:24174175; https://doi.org/10.1002/ijc.28541
   PubMed Web of Science ®Google Scholar
• Puig-Junoy J , Lopez-Valcarcel BG . Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained. Prev Med 2009; 48(5):444-8; PMID:19232368; https://doi.org/10.1016/j.ypmed.2009.02.011
   PubMed Web of Science ®Google Scholar
• Cuzick J , Ho L , Terry G , Kleeman M , Giddings M , Austin J , Cadman L , Ashdown-Barr L , Costa MJ , Szarewski A . Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J Clin Virol 2014; 60(1):44-9; PMID:24630483; https://doi.org/10.1016/j.jcv.2014.02.002
   PubMed Web of Science ®Google Scholar
• Cuzick J . Gardasil 9 joins the fight against cervix cancer. Expert Rev Vaccines 2015; 14(8):1047-9; PMID:26028344; https://doi.org/10.1586/14760584.2015.1051470
   PubMed Web of Science ®Google Scholar
• Angioli R , Lopez S , Aloisi A , Terranova C , De Cicco C , Scaletta G , Capriglione S , Miranda A , Luvero D , Ricciardi R , et al. Ten years of HPV vaccines: State of art and controversies. Crit Rev Oncol Hematol 2016; 102:65-72; PMID:27066937; https://doi.org/10.1016/j.critrevonc.2016.03.020
   PubMed Web of Science ®Google Scholar
• Lukai Z , Ebenezer T . Gardasil-9: A global survey of projected efficacy. Antiviral Res 2016; 130:101-9; PMID:27040313; https://doi.org/10.1016/j.antiviral.2016.03.016
   PubMed Web of Science ®Google Scholar
• Stokley S , Jeyarajah J , Yankey D , Cano M , Gee J , Roark J , Robinette CC , Markowitz, L . Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014 — United States. Morb Mortal Wkly Rep 2014; 63(29):620-4; PMID:25055185; https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6329a3.htm [Accessed on 20 April 2017 ]
   PubMed Web of Science ®Google Scholar
• Voss DS , Wofford LG . Human Papillomavirus vaccine uptake in Adolescent Boys: An evidence review. Worldviews Evid Based Nurs 2016; 13(5):390-5; PMID:27458811; https://doi.org/10.1111/wvn.12172
   PubMed Web of Science ®Google Scholar
• Nanagas VC , Stolfi A , Nanagas MT , Eberhart GM , Alter SJ . Adolescent Male Human Papillomavirus Vaccination. Glob Pediatr Health 2016; 3:2333794X16642373; PMID:27336012; https://doi.org/10.1177/2333794X16642373
   PubMedGoogle Scholar
• Yang DY , Bracken K . Update on the new 9-valent vaccine for human papillomavirus prevention. Can Fam Physician 2016; 62(5):399-402; PMID:27255620; http://www.cfp.ca/content/cfp/62/5/399.full.pdf
   PubMed Web of Science ®Google Scholar
• Bratic JS , Seyferth ER , Bocchini JA, Jr . Update on barriers to human papillomavirus vaccination and effective strategies to promote vaccine acceptance. Curr Opin Pediatr 2016; 28(3):407-12; PMID:27093354; https://doi.org/10.1097/MOP.0000000000000353
   PubMed Web of Science ®Google Scholar
• Markowitz LE , Meites E , Unger ER . Two vs Three Doses of Human Papillomavirus Vaccine: New policy for the second decade of the vaccination program. JAMA 2016; 316(22):2370-2; PMID:27893046; https://doi.org/10.1001/jama.2016.16393
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC) . Vaccines for Children Program (VFC). Prices last reviewed/updated: April 3, 2017; Available at: http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/ [Accessed on 20 April 2017 ]
   Google Scholar
• Massa S , Paolini F , Curzio G , Cordeiro MN , Illiano E , Demurtas OC , Franconi R , Venuti A . A plant protein signal sequence improved humoral immune response to HPV prophylactic and therapeutic DNA vaccines. Hum Vaccin Immunother 2017; 13(2):271-82; PMID:28118086; https://doi.org/10.1080/21645515.2017.1264766
   PubMed Web of Science ®Google Scholar
• Wu CC , Wu FC , Hsu YT , Hsiao YC , Yang YC , Chang CA , Chang CL . Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer. Oncotarget 2017; 8(20):33024-36; PMID:28423693; https://doi.org/10.18632/oncotarget.16032
   PubMed Web of Science ®Google Scholar
• Joura EA , Giuliano AR , Iversen OE , Bouchard C , Mao C , Mehlsen J , Moreira ED, Jr , Ngan Y , Petersen LK , Lazcano-Ponce E , et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372(8):711-23; PMID:25693011; https://doi.org/10.1056/NEJMoa1405044
   PubMed Web of Science ®Google Scholar
• Pastrana DV , Gambhira R , Buck CB , Pang YY , Thompson CD , Culp TD , Christensen ND , Lowy DR , Schiller JT , Roden RB . Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005; 337(2):365-72; PMID:15885736; https://doi.org/10.1016/j.virol.2005.04.011
   PubMed Web of Science ®Google Scholar
• Seitz H , Canali E , Ribeiro-Müller L , Pàlfi A , Bolchi A , Tommasino M , Ottonello S , Müller M . A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses. Vaccine 2014; 32(22):2610-7; PMID:24662712; https://doi.org/10.1016/j.vaccine.2014.03.033
   PubMed Web of Science ®Google Scholar
• Schellenbacher C , Roden RB , Kirnbauer R . Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 2009; 83(19):10085-95; PMID:19640991; https://doi.org/10.1128/JVI.01088-09
   PubMed Web of Science ®Google Scholar
• Schellenbacher C , Roden RB , Kirnbauer R . Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res 2017; 231:166-75; PMID:27889616; https://doi.org/10.1016/j.virusres.2016.11.020
   PubMed Web of Science ®Google Scholar
• Roden RB , Yutzy WH , Fallon R , Inglis S , Lowy DR , Schiller JT . Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000; 270(2):254-7; PMID:10792983; https://doi.org/10.1006/viro.2000.0272
   PubMed Web of Science ®Google Scholar
• Tumban E , Peabody J , Peabody DS , Chackerian B . A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 2011; 6(8):e23310; PMID:21858066; https://doi.org/10.1371/journal.pone.0023310
   PubMed Web of Science ®Google Scholar
• Zhang X , Li S , Modis Y , Li Z , Zhang J , Xia N , Zhao Q . Functional assessment and structural basis of antibody binding to human papillomavirus capsid. Rev Med Virol 2016; 26(2):115-28; PMID:26676802; https://doi.org/10.1002/rmv.1867
   PubMed Web of Science ®Google Scholar